HIV drugs
SAN FRANCISCO — A federal court in California preliminarily approved a $10 million settlement between Bristol-Myers Squibb and end-payor plaintiffs, which claimed the company and other pharmaceutical companies engaged in anti-competitive practices that kept less expensive generic HIV drugs from being available to the class members.
Brief / December 14, 2021
Read the order here.
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing
trials, major litigation and rulings in courthouses around the U.S. and the world, while the
monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech
and the arts.